EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 2% Higher

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) rose 2% during mid-day trading on Tuesday . The stock traded as high as $21.72 and last traded at $21.71. Approximately 27,523 shares were traded during trading, a decline of 97% from the average daily volume of 944,644 shares. The stock had previously closed at $21.28.

Analyst Ratings Changes

A number of brokerages have commented on EYPT. Mizuho increased their target price on EyePoint Pharmaceuticals from $30.00 to $39.00 and gave the company a "buy" rating in a report on Friday, February 16th. HC Wainwright decreased their target price on shares of EyePoint Pharmaceuticals from $35.00 to $33.00 and set a "buy" rating on the stock in a research note on Tuesday, January 16th. Capital One Financial restated an "overweight" rating on shares of EyePoint Pharmaceuticals in a report on Friday, February 16th. Finally, JPMorgan Chase & Co. began coverage on shares of EyePoint Pharmaceuticals in a research report on Monday, January 22nd. They set an "overweight" rating and a $35.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $33.86.

EyePoint Pharmaceuticals Trading Up 2.6 %

The firm has a 50 day moving average price of $24.45 and a 200-day moving average price of $18.15. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -11.84 and a beta of 1.64.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.27. EyePoint Pharmaceuticals had a negative return on equity of 61.48% and a negative net margin of 153.84%. The firm had revenue of $14.03 million during the quarter, compared to the consensus estimate of $8.71 million. During the same period in the previous year, the firm posted ($0.61) EPS. As a group, equities analysts expect that EyePoint Pharmaceuticals, Inc. will post -1.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other EyePoint Pharmaceuticals news, insider Dario A. Paggiarino sold 5,135 shares of the firm's stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $25.00, for a total value of $128,375.00. Following the sale, the insider now directly owns 36,505 shares of the company's stock, valued at approximately $912,625. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other EyePoint Pharmaceuticals news, insider Dario A. Paggiarino sold 5,135 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $25.00, for a total transaction of $128,375.00. Following the transaction, the insider now owns 36,505 shares of the company's stock, valued at $912,625. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Dario A. Paggiarino sold 49,325 shares of the stock in a transaction on Friday, January 26th. The stock was sold at an average price of $25.66, for a total value of $1,265,679.50. Following the completion of the transaction, the insider now directly owns 36,505 shares in the company, valued at $936,718.30. The disclosure for this sale can be found here. Insiders have sold a total of 56,169 shares of company stock valued at $1,437,509 in the last quarter. 13.05% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Deutsche Bank AG boosted its stake in shares of EyePoint Pharmaceuticals by 4.0% during the 3rd quarter. Deutsche Bank AG now owns 21,764 shares of the company's stock valued at $174,000 after buying an additional 830 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in EyePoint Pharmaceuticals by 6.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,584 shares of the company's stock valued at $360,000 after acquiring an additional 882 shares during the last quarter. American International Group Inc. grew its holdings in EyePoint Pharmaceuticals by 10.2% during the 1st quarter. American International Group Inc. now owns 12,370 shares of the company's stock worth $150,000 after acquiring an additional 1,142 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter worth about $27,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of EyePoint Pharmaceuticals by 36.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,724 shares of the company's stock valued at $109,000 after purchasing an additional 1,250 shares in the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.